Merck & Co., Inc., which operates outside the U.S. and Canada as MSD, today announced the European Commission (EC) approval of ELONVA® (corifollitropin alfa injection).
ELONVA is indicated for controlled ovarian stimulation (COS) in combination with a GnRH antagonist for the development of multiple follicles in women participating in an assisted reproductive technology program.
With the EC approval, Merck receives marketing authorization for ELONVA with unified labeling valid in all European Union Member States.
“The European approval of ELONVA is a positive step towards reducing the burden of injections for women experiencing difficulty conceiving,” said Mirjam Mol-Arts, senior vice president, Merck Research Laboratories. “Merck is proud of the company’s women’s health portfolio and is committed to providing effective patient-focused fertility treatments.”
ELONVA is the first sustained follicle stimulant. Due to its ability to initiate and sustain multiple follicular growth for an entire week, a single subcutaneous injection of the recommended dose of ELONVA may replace the first seven injections of any conventional daily recombinant follicle stimulating hormone (rFSH) preparation in a COS treatment cycle.